BeOne Medicines Shares Jump Over 6% Premarket as Nine-Month Net Profit Surges 431.8%

Stock News11-05

On Thursday, BeOne Medicines Ltd. (ONC.US) shares climbed more than 6% in premarket trading to $402.98.

Financial results showed that the company posted total operating revenue of RMB 34.993 billion for the first three quarters, up 26.8% year on year, while net profit attributable to shareholders reached RMB 6.055 billion, up 431.8% year on year.

On a quarterly basis, the company recorded total operating revenue of RMB 12.774 billion in the third quarter, up 26.8% year on year, with net profit attributable to shareholders of RMB 2.785 billion, up 304.3% year on year.

In the third quarter of 2026, product revenue reached RMB 12.560 billion, compared with RMB 9.954 billion in the same period last year. The growth in product revenue was mainly driven by increased sales of the company's self-developed products BRUKINSA® (zanubrutinib capsules) and TEVIMBRA® (tislelizumab injection), as well as Amgen-licensed products.

BeOne Medicines further raised its full-year guidance, stating that it expects 2026 operating revenue to be between RMB 46.3 billion and RMB 47.0 billion, up from its previous forecast of RMB 44.9 billion to RMB 46.2 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment